Immunotherapy boosts standard treatment for head and neck cancer in early trial
NCT ID NCT02586207
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 34 times
Summary
This early-phase trial tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiation is safe and effective for people with advanced head and neck cancer. 59 participants received pembrolizumab before, during, and after their regular treatment. The goal was to see if this combination could improve tumor shrinkage and control the disease, while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sanford Health Cancer Center
Sioux Falls, South Dakota, 57104, United States
-
Sanford-Bismarck Medical Center
Bismarck, North Dakota, 58501, United States
-
Sanford-Roger Maris Cancer Center
Fargo, North Dakota, 58122, United States
-
UCSD Moores Cancer Center
La Jolla, California, 92093-0698, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.